LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

Home・Akcijų sąrašas・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

34.03 -0.82

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

33.27

Max

34.2

Pagrindiniai rodikliai
By Trading Economics
Pajamos	11M 51M
Pardavimai	39M 239M
P/E Sektoriaus vid.	10.038 105.69
Pelnas, tenkantis vienai akcijai	1.08
Pelno marža	21.242
Darbuotojai	268
EBITDA	12M 71M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+34.15% upside

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	145M 1.8B
Ankstesnė atidarymo kaina	34.85
Ankstesnė uždarymo kaina	34.03

Naujienos nuotaikos

By Acuity

45%

55%

167 / 374 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

29.8 / N/A Palaikymas ir pasipriešinimas

Harmony Biosciences Holdings Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-11-14 17:45; UTC

Uždarbis

Pagrindinės rinkos jėgos

Figure Technology Shares Rise After Higher 3Q Earnings, Revenue

2025-11-14 17:31; UTC

Uždarbis

Pagrindinės rinkos jėgos

American Bitcoin Advances on 3Q Profit, Eric Trump's Crypto Confidence

2025-11-14 16:15; UTC

Pagrindinės rinkos jėgos

Scholar Rock Shares Rise on Renewed Apitegromab Hopes

2025-11-14 23:56; UTC

Įsigijimai, susijungimai, perėmimai

Berkshire Hathaway Bought Alphabet Shares Worth $4.3 Billion in the Third Quarter. Here's What It Sold. -- Barrons.com

2025-11-14 23:02; UTC

Rinkos pokalbiai

Chinese Battery Makers Benefit From U.S. Rising Demand -- Market Talk

2025-11-14 22:35; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

The Score: Tyson, Robinhood, Walmart, Paramount Skydance and More Stocks That Defined the Week -- WSJ

2025-11-14 22:32; UTC

Įsigijimai, susijungimai, perėmimai

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- 2nd Update

2025-11-14 22:29; UTC

Uždarbis

Starbucks Scores on Holiday Sales. It's a Good Sign for the Turnaround. -- Barrons.com

2025-11-14 22:00; UTC

Įsigijimai, susijungimai, perėmimai

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- Update

2025-11-14 21:50; UTC

Rinkos pokalbiai

Uždarbis

Tech, Media & Telecom Roundup: Market Talk

2025-11-14 21:18; UTC

Įsigijimai, susijungimai, perėmimai

Berkshire Buys Shares of Alphabet and Pares Apple Stake -- WSJ

2025-11-14 20:27; UTC

Rinkos pokalbiai

Oil Futures Rise After Ukraine Strikes Russian Port -- Market Talk

2025-11-14 20:23; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Post Weekly Gain -- Market Talk

2025-11-14 20:17; UTC

Įsigijimai, susijungimai, perėmimai

Several State Attorneys General Oppose Railroad Merger -- WSJ

2025-11-14 19:29; UTC

Rinkos pokalbiai

Uždarbis

Applied Materials' F4Q Results Seen as 'Uninspiring' -- Market Talk

2025-11-14 18:44; UTC

Rinkos pokalbiai

Uždarbis

Disney's Growth Now Hinges More on ESPN -- Market Talk

2025-11-14 18:27; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-11-14 18:27; UTC

Rinkos pokalbiai

Morgan Stanley Sees 'Worthy Successor' in Walmart CEO Furner -- Market Talk

2025-11-14 18:20; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Rises by 3 to 417 -- Market Talk

2025-11-14 17:20; UTC

Rinkos pokalbiai

Uždarbis

Auto & Transport Roundup: Market Talk

2025-11-14 17:20; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Health Care Roundup: Market Talk

2025-11-14 17:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-11-14 16:51; UTC

Rinkos pokalbiai

Starbucks Gets Holiday Sales Lift -- Market Talk

2025-11-14 16:48; UTC

Rinkos pokalbiai

Gold Slides Amid Selloff, Lower December Fed Rate-Cut Expectations -- Market Talk

2025-11-14 16:38; UTC

Rinkos pokalbiai

Unica Reports Higher Brazilian Sugar and Ethanol Production -- Market Talk

2025-11-14 16:30; UTC

Įsigijimai, susijungimai, perėmimai

Merck Is Paying Up for Flu Biotech as M&A Spree Continues -- Barrons.com

2025-11-14 16:28; UTC

Rinkos pokalbiai

Ukraine Strike on Russian Port Lifts Distillates -- Market Talk

2025-11-14 15:59; UTC

Rinkos pokalbiai

U.S. Natural Gas Inventories Rise More Than Expected -- Market Talk

2025-11-14 15:06; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-11-14 15:06; UTC

Rinkos pokalbiai

Dollar Could Benefit From U.K., French Fiscal Concerns -- Market Talk

Akcijų palyginimas

Kainos pokytis

Harmony Biosciences Holdings Inc Prognozė

Kainos tikslas

By TipRanks

34.15% į viršų

12 mėnesių prognozė

Vidutinis 46 USD 34.15%

Aukščiausias 62 USD

Žemiausias 32 USD

Remiantis 10 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Harmony Biosciences Holdings Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

10 ratings

Pirkti

Laikyti

Parduoti

Remiantis 10 analitikų, pateikusių Harmony Biosciences Holdings Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

29.8 / N/APalaikymas ir pasipriešinimas

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Rinkos nuotaikos

By Acuity

167 / 374 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.